Guggenheim Maintains Buy on Medpace Hldgs, Raises Price Target to $464
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Sandy Draper maintains a Buy rating on Medpace Holdings (MEDP) and raises the price target from $453 to $464.
April 24, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Sandy Draper maintains a Buy rating on Medpace Holdings and raises the price target from $453 to $464.
The increase in price target by a reputable analyst like Sandy Draper suggests a strong confidence in Medpace Holdings' future performance. This endorsement is likely to positively influence investor sentiment and potentially drive up MEDP's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100